{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:25:18Z","timestamp":1789853118381,"version":"4.0.1"},"reference-count":78,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T00:00:00Z","timestamp":1446508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0141104","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T19:00:20Z","timestamp":1446577220000},"page":"e0141104","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review"],"prefix":"10.1371","volume":"10","author":[{"given":"Abigail","family":"Stevely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munyaradzi","family":"Dimairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Julious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Nicholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,11,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1740774510361542","article-title":"Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development","volume":"7","author":"J Quinlan","year":"2010","journal-title":"Clinical trials (London, England)"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/sim.2763","article-title":"A 25-year review of sequential methodology in clinical studies","volume":"26","author":"S Todd","year":"2007","journal-title":"Statistics in medicine"},{"key":"ref3","unstructured":"FDA (2010) Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1740774512461859","article-title":"Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop","volume":"9","author":"CS Coffey","year":"2012","journal-title":"Clinical trials (London, England)"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1745-6215-13-145","article-title":"Adaptive trial designs: a review of barriers and opportunities","volume":"13","author":"J a Kairalla","year":"2012","journal-title":"Trials"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/1745-6215-15-383","article-title":"Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency","volume":"15","author":"A Els\u00e4\u00dfer","year":"2014","journal-title":"Trials"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/2168479014522468","article-title":"Adaptive Design: Results of 2012 Survey on Perception and Use","volume":"48","author":"CC Morgan","year":"2014","journal-title":"Therapeutic Innovation & Regulatory Science"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10543400600609718","article-title":"Adaptive design in clinical research: issues, opportunities, and recommendations","volume":"16","author":"M Chang","year":"2006","journal-title":"Journal of biopharmaceutical statistics"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/10543406.2010.514456","article-title":"FDA draft guidance on adaptive design clinical trials: Pfizer\u2019s perspective","volume":"20","author":"C Chuang-Stein","year":"2010","journal-title":"Journal of biopharmaceutical statistics"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/009286150904300503","article-title":"Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development","volume":"43","author":"B Gaydos","year":"2009","journal-title":"Therapeutic Innovation & Regulatory Science"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/10543406.2010.514462","article-title":"Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives","volume":"20","author":"Q Liu","year":"2010","journal-title":"Journal of biopharmaceutical statistics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-med-092012-112310","article-title":"Adaptive clinical trial design","volume":"65","author":"S-C Chow","year":"2014","journal-title":"Annual review of medicine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-3-11","article-title":"Adaptive design methods in clinical trials\u2014a review","volume":"3","author":"S-C Chow","year":"2008","journal-title":"Orphanet journal of rare diseases"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/216847900604000409","article-title":"Implementing adaptive designs: logistical and operational considerations","volume":"40","author":"J Quinlan","year":"2006","journal-title":"Drug Information Journal"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13063-015-0958-9","article-title":"Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials","volume":"16","author":"M Dimairo","year":"2015","journal-title":"Trials"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"C Begg","year":"1996","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"KF Schulz","year":"2010","journal-title":"Annals of internal medicine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"D Moher","year":"2001","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1001\/jama.285.15.1996","article-title":"Value of flow diagrams in reports of randomized controlled trials","volume":"285","author":"M Egger","year":"2001","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.285.15.1992","article-title":"Use of the CONSORT Statement and Quality of Reports of Randomized Trials","volume":"285","author":"D Moher","year":"2001","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/2046-4053-1-60","article-title":"Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review","volume":"1","author":"L Turner","year":"2012","journal-title":"Systematic reviews"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1002\/sim.5402","article-title":"Improving the reporting of randomised trials: the CONSORT Statement and beyond","volume":"31","author":"DG Altman","year":"2012","journal-title":"Statistics in medicine"},{"key":"ref23","first-page":"e5661","article-title":"Consort 2010 statement: extension to cluster randomised trials","volume":"345","author":"MK Campbell","year":"2012","journal-title":"BMJ (Clinical research ed)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"G Piaggio","year":"2012","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"a2390","DOI":"10.1136\/bmj.a2390","article-title":"Improving the reporting of pragmatic trials: an extension of the CONSORT statement","volume":"337","author":"M Zwarenstein","year":"2008","journal-title":"BMJ (Clinical research ed)"},{"key":"ref26","unstructured":"The EQUATOR Network (n.d.) Enhancing the QUAlity and Transparency Of health Research: Reporting guidelines under development. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.equator-network.org\/library\/reporting-guidelines-under-development\/\" xlink:type=\"simple\">http:\/\/www.equator-network.org\/library\/reporting-guidelines-under-development\/<\/ext-link>. Accessed 23 September 2014."},{"key":"ref27","unstructured":"Detry M, Lewis R, Broglio K, Connor J (2012) Standards for the Design, Conduct, and Evaluation of Adaptive Randomized Clinical Trials."},{"key":"ref28","unstructured":"SAACTD Workshop Committee (2009) Connecting Non-Profits to Adaptive Clinical Trial Designs: Themes and Recommendations from the Scientific Advances in Adaptive Clinical Trial Designs Workshop. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/custom.cvent.com\/536726184EFD40129EF286585E55929F\/files\/2627e73646ce4733a2c03692fab26fff.pdf\" xlink:type=\"simple\">https:\/\/custom.cvent.com\/536726184EFD40129EF286585E55929F\/files\/2627e73646ce4733a2c03692fab26fff.pdf<\/ext-link>. Accessed 3 October 2014."},{"key":"ref29","unstructured":"U.S. National Institutes of Health (n.d.) ClinicalTrials.gov. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/<\/ext-link>. Accessed 1 June 2014."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/2046-4053-3-54","article-title":"Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram","volume":"3","author":"E Stovold","year":"2014","journal-title":"Systematic reviews"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS medicine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: Comparison of seven methods","volume":"17","author":"RG Newcombe","year":"1998","journal-title":"Statistics in Medicine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176344552","article-title":"Bootstrap Methods: Another Look at the Jackknife","volume":"7","author":"B Efron","year":"1979","journal-title":"The Annals of Statistics"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"K Lan","year":"1983","journal-title":"Biometrika"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"P O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","article-title":"Group Sequential Methods in the Design and Analysis of Clinical Trials","volume":"64","author":"SJ Pocock","year":"1977","journal-title":"Biometrika"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","article-title":"Repeated assessment of results in clinical trials of cancer treatment","volume":"44","author":"J Haybittle","year":"1971","journal-title":"The British journal of radiology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples","volume":"35","author":"R Peto","year":"1977","journal-title":"British journal of cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-3758(94)90187-2","article-title":"Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis","volume":"42","author":"S Pampallona","year":"1994","journal-title":"Journal of Statistical Planning and Inference"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/sim.4780091207","article-title":"Group sequential designs using a family of type I error probability spending functions","volume":"9","author":"IK Hwang","year":"1990","journal-title":"Statistics in medicine"},{"key":"ref41","first-page":"148","article-title":"Group Sequential Methods with Applications to Clinical Trials","author":"C Jennison","year":"2000"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2307\/2531959","article-title":"Approximately optimal one-parameter boundaries for group sequential trials","volume":"43","author":"S Wang","year":"1987","journal-title":"Biometrics"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"TR Fleming","year":"1982","journal-title":"Biometrics"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/(SICI)1097-0258(19990915\/30)18:17\/18<2271::AID-SIM254>3.0.CO;2-Z","article-title":"A unified theory for sequential clinical trials","volume":"18","author":"J Whitehead","journal-title":"Statistics in medicine"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1016\/j.ejca.2013.06.043","article-title":"Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival","volume":"49","author":"W Tr\u00f6ger","year":"2013","journal-title":"European journal of cancer (Oxford, England: 1990)"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"C Butts","year":"2014","journal-title":"The Lancet Oncology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"G Middleton","year":"2014","journal-title":"The Lancet Oncology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1740774511399128","article-title":"The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease","volume":"8","author":"Y Pritchett","year":"2011","journal-title":"Clinical trials (London, England)"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Thadhani R, Wenger J, Tamez H, Cannata J, Thompson BT, et al. (2012) Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease. 02114.","DOI":"10.1001\/jama.2012.120"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"AC Wolff","year":"2013","journal-title":"Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer","volume":"367","author":"RS Mehta","year":"2012","journal-title":"The New England journal of medicine"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ophtha.2013.10.027","article-title":"Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study","volume":"121","author":"EY Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/biomet\/77.4.875","article-title":"Parameter estimation following group sequential hypothesis testing","volume":"77","author":"S Emerson","year":"1990","journal-title":"Biometrika"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1001\/jama.2010.1796","article-title":"Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial","volume":"304","author":"L Mascia","year":"2010","journal-title":"JAMA"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1200\/JCO.2003.02.098","article-title":"Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12\u20139566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"MJ Moore","year":"2003","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"M Markman","year":"2003","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/eye.2014.206","article-title":"The reporting quality of parallel randomised controlled trials in ophthalmic surgery in 2011: a systematic review","volume":"28","author":"AC Yao","year":"2014","journal-title":"Eye (London, England)"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.ebd.6400796","article-title":"Quality of reporting randomised controlled trials in major dental journals suboptimal","volume":"12","author":"D Hurst","year":"2011","journal-title":"Evidence-based dentistry"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/sj.bdj.4801304","article-title":"Quality of reporting randomised clinical trials in dental and medical research","volume":"192","author":"P Sj\u00f6gren","year":"2002","journal-title":"British dental journal"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ijcard.2012.12.020","article-title":"An assessment of the reporting quality of randomised controlled trials relating to anti-arrhythmic agents (2002\u20132011)","volume":"168","author":"CF Camm","year":"2013","journal-title":"International journal of cardiology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jclinepi.2011.10.016","article-title":"Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols","volume":"65","author":"R Mhaskar","year":"2012","journal-title":"Journal of clinical epidemiology"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit: a systematic review","volume":"294","author":"VM Montori","year":"2005","journal-title":"JAMA"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jclinepi.2007.07.016","article-title":"Early stopping of randomized clinical trials for overt efficacy is problematic","volume":"61","author":"D Bassler","year":"2008","journal-title":"Journal of clinical epidemiology"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.2010.310","article-title":"Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis","volume":"303","author":"D Bassler","year":"2010","journal-title":"JAMA"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.annemergmed.2014.12.020","article-title":"Are We There Yet? Early Stopping in Clinical Trials","volume":"65","author":"RL Wears","year":"2015","journal-title":"Annals of Emergency Medicine"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1158\/1078-0432.CCR-11-3118","article-title":"Overestimation of the effect size in group sequential trials","volume":"18","author":"JJ Zhang","year":"2012","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/1740774512454600","article-title":"Stopping a trial early\u2014and then what?","volume":"9","author":"J Wittes","year":"2012","journal-title":"Clinical trials (London, England)"},{"key":"ref68","first-page":"294","article-title":"When to stop a clinical trial early for benefit: Lessons learned and future approaches","volume":"5","author":"F Zannad","year":"2012","journal-title":"Circulation: Heart Failure"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1740774509102310","article-title":"Stopping clinical trials early for benefit: impact on estimation","volume":"6","author":"B Freidlin","year":"2009","journal-title":"Clinical trials (London, England)"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2307\/2531502","article-title":"Point estimation following group sequential tests","volume":"45","author":"K Kim","year":"1989","journal-title":"Biometrics"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/biomet\/83.2.453","article-title":"Point and interval estimation following a sequential clinical trial","volume":"83","author":"S Todd","year":"1996","journal-title":"Biometrika"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/biomet\/86.1.71","article-title":"Unbiased estimation following a group sequential test","volume":"86","author":"A Liu","year":"1999","journal-title":"Biometrika"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/biomet\/73.3.573","article-title":"On the bias of maximum likelihood estimation following a sequential test","volume":"73","author":"J Whitehead","year":"1986","journal-title":"Biometrika"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1006\/cbmr.1993.1004","article-title":"Computation of the uniform minimum variance unbiased estimator of a normal mean following a group sequential trial","volume":"26","author":"SS Emerson","year":"1993","journal-title":"Computers and biomedical research, an international journal"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2307\/2533122","article-title":"A computationally simpler algorithm for the UMVUE of a normal mean following a group sequential trial","volume":"53","author":"S Emerson","year":"1997","journal-title":"Biometrics"},{"key":"ref76","article-title":"Estimation After a Group Sequential Trial","author":"E Milanzi","year":"2014","journal-title":"Statistics in Biosciences"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1750-1172-6-79","article-title":"Benefits, challenges and obstacles of adaptive clinical trial designs","volume":"6","author":"C Chow S-","year":"2011","journal-title":"Orphanet journal of rare diseases"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(13)62228-X","article-title":"Reducing waste from incomplete or unusable reports of biomedical research","volume":"383","author":"P Glasziou","year":"2014","journal-title":"Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0141104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T06:52:16Z","timestamp":1567320736000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0141104"}},"subtitle":[],"editor":[{"given":"Mohammed","family":"Shamji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,3]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0141104","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,3]]}}}